Why Social Networks Matter in the Uptake of New Medicines

Why Social Networks Matter in the Uptake of New Medicines

The uptake of new medicines is often explained through a familiar set of drivers: clinical efficacy, regulatory approval, reimbursement status, and promotional activity. While these factors are necessary, they are rarely sufficient. Evidence from health services research consistently shows that medicines spread through healthcare systems via social and professional networks, not in isolation.

A growing body of academic literature demonstrates that prescribing behaviour is shaped as much by who clinicians interact with as by the evidence they receive. For pharmaceutical and biotechnology leaders, this insight has important implications for forecasting uptake, designing engagement strategies, and understanding why adoption varies across regions and institutions.

Prescribing as a social process

The 2014 BMC Health Services Research paper provides a clear starting point. The authors show that physicians are embedded in professional networks through shared workplaces, referral patterns, training histories, and informal peer relationships. These networks act as channels through which information, norms, and behaviours flow.

When a new medicine is introduced, clinicians do not evaluate it independently. Instead, they observe how peers respond, discuss experiences in formal and informal settings, and update their beliefs based on trusted colleagues’ actions. As a result, adoption decisions are socially conditioned rather than purely individual.

The paper highlights that clinicians who are more centrally positioned within networks are more likely to influence the prescribing behaviour of others. These individuals often act as early adopters whose decisions reduce uncertainty for their peers.

Network effects and uneven diffusion

One of the most important findings in the literature is that uptake does not occur evenly across the healthcare system. Instead, it clusters.

Hospitals, regions, and practices with dense internal networks often show faster adoption once an innovation gains acceptance locally. In contrast, loosely connected settings may lag, even when exposed to the same evidence and promotional inputs.

This pattern reflects classic network effects. As more clinicians within a network adopt a medicine, the perceived risk of adoption decreases. Shared experiences create informal validation, making continued diffusion more likely. The result is a self-reinforcing process where adoption accelerates within connected groups while remaining slow elsewhere.

For commercial teams, this explains why some markets appear to “tip” rapidly while others stagnate despite similar investment.

Linking networks to Bass diffusion

These observations align closely with the Bass diffusion model, which distinguishes between innovation effects and imitation effects.

In the Bass framework, early adopters are driven by external information such as clinical trial data, guidelines, and regulatory milestones. Later adopters are influenced primarily by social contagion, meaning they adopt because others around them already have.

Professional networks provide the mechanism through which imitation operates in healthcare. Peer prescribing acts as a signal that a medicine is safe, effective, and appropriate for real-world use. The BMC paper reinforces this by showing that peer exposure significantly increases the likelihood of adoption, even after controlling for other factors.

From a forecasting perspective, this means that uptake curves cannot be understood without accounting for network structure. Two medicines with similar clinical profiles can experience very different diffusion trajectories depending on how quickly they penetrate influential networks.

Patients as networked decision-makers

Although the paper focuses primarily on clinicians, the same logic increasingly applies to patients.

Patients are no longer passive recipients of treatment decisions. They exchange information through family networks, peer support groups, and online communities. These patient networks shape awareness, expectations, and willingness to initiate or persist with treatment.

When clinicians and patients are both embedded in reinforcing networks, adoption can accelerate. When their networks send conflicting signals, uptake may stall. For example, a clinician network may be cautiously supportive while patient communities express concern about side effects or access, slowing real-world use.

Understanding both sides of the network equation is therefore essential for anticipating real-world outcomes.

Strategic implications for pharma and biotech

The findings from this research have several implications for leaders responsible for strategy, market access, and forecasting.

First, influence is not proportional to reach. Identifying highly connected clinicians is often more valuable than maximising contact volume.

Second, early uptake should be interpreted through a network lens. Slow initial adoption may reflect network structure rather than lack of product value.

Third, forecasting models that ignore network effects risk systematic error. Diffusion is path-dependent, and early network penetration can materially alter long-term outcomes.

Finally, ethical engagement remains critical. The goal is not to manipulate networks, but to understand how information and experience flow through them so that evidence can be shared more effectively and equitably.

From evidence to insight

The academic literature is clear. Social and professional networks are not peripheral to medicine uptake. They are central.

For pharmaceutical and biotechnology organisations operating in increasingly complex and constrained environments, incorporating network analysis into strategy is no longer optional. It is a prerequisite for understanding how innovation actually reaches patients.

References

Burt, R.S. (2004). Structural holes and good ideas. American Journal of Sociology, 110(2), 349–399.

Rogers, E.M. (2003). Diffusion of Innovations (5th ed.). New York: Free Press.

Van den Bulte, C. and Lilien, G.L. (2001). Medical innovation revisited: Social contagion versus marketing effort. American Journal of Sociology, 106(5), 1409–1435.

BMC Health Services Research (2014). Social networks and physician adoption of new medicines. BMC Health Services Research, 14, 469.

‍